XSNX (Novaccess Global) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Novaccess Global Change In Receivables?

Novaccess Global's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Novaccess Global's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Novaccess Global's change in receivables for the fiscal year that ended in Sep. 2023 was $0.00 Mil. It means Novaccess Global's Accounts Receivable stayed the same from Sep. 2022 to Sep. 2023 .

Novaccess Global's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novaccess Global's liquidation value for the three months ended in Mar. 2024 was $-6.93 Mil.

Novaccess Global Change In Receivables Historical Data

The historical data trend for Novaccess Global's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global Change In Receivables Chart

Novaccess Global Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

-0.09

Novaccess Global Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Novaccess Global Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Novaccess Global (OTCPK:XSNX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Novaccess Global's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Novaccess Global's accounts receivable are only considered to be worth 75% of book value:

Novaccess Global's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.01	-	6.94	+	0.75 * 0	+	0.5 * 0
=	-6.93

Novaccess Global Change In Receivables Related Terms

Thank you for viewing the detailed overview of Novaccess Global's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novaccess Global Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023

Website

https://www.novaccessglobal.com

Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.

Executives

Jason Michael Anderson	director	8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini	director	880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird	officer: Chief Financial Officer
Larry Michael Yukich	officer: Chief Financial Officer	8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin	officer: Chief Executive Officer	8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc.	10 percent owner	8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin	director, 10 percent owner, officer: Chief Executive Officer	8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak	director
Osmund Mark Fundingsland	director	1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson	director	2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt	officer: CFO	10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes	officer: COO	6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich	director, 10 percent owner, officer: President	23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian	director, officer: Secretary	626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich	director, officer: President	1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404